SCHEDULE: Morgan Stanley Reduces Stake in Pliant Therapeutics

Morgan Stanley has reported a reduction in its beneficial ownership of Pliant Therapeutics, Inc. common stock to below 5%.

Summary

• Morgan Stanley filed an Amendment No. 1 to Schedule 13G, disclosing its ownership in PLIANT THERAPEUTICS, INC.
• As of December 31, 2025, Morgan Stanley beneficially owned 545,228 shares of Pliant Therapeutics' Common Stock.
• This ownership represents 0.9% of the class of securities, indicating a reduction from a previous holding that was above the 5% reporting threshold.
• Morgan Stanley holds shared voting power over 544,224 shares and shared dispositive power over 545,228 shares.
• The filing confirms that Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities.

Sentiment

Score: 5

Explanation: Neutral. This is a routine disclosure of an institutional investor reducing its stake below a reporting threshold. It doesn't inherently convey positive or negative sentiment about the issuer's performance, but rather reflects a change in the investor's position.

Positives

• The filing represents a routine disclosure of an institutional investor adjusting its position, which is a normal part of portfolio management.

Negatives

• Morgan Stanley's reduction of its stake below the 5% threshold could be interpreted as a decrease in institutional conviction, although it is a common portfolio management activity.

Industry Context

This filing reflects a routine adjustment in institutional ownership, common within the investment industry. While Pliant Therapeutics operates in the biopharmaceutical sector, which often sees dynamic institutional investment based on clinical developments and market sentiment, this specific disclosure primarily indicates a portfolio rebalancing by Morgan Stanley rather than a direct commentary on industry trends.

Comparison to Industry Standards

• Institutional investors like Morgan Stanley frequently adjust their holdings in public companies, including those in the biopharmaceutical sector, as part of their ongoing portfolio management strategies.
• A reduction in ownership below a 5% threshold is a standard event that triggers a Schedule 13G amendment, reflecting compliance with regulatory disclosure requirements.
• Such adjustments are often driven by internal investment mandates, risk management, or rebalancing efforts, and are not uncommon when compared to the activities of other large investment banks and asset managers.

Stakeholder Impact

• Shareholders: May observe a slight decrease in institutional support, which could marginally influence short-term trading sentiment.
• Company Management: Will note the change in institutional ownership as part of ongoing investor relations monitoring.

Key Dates

Recommendation

This Schedule 13G filing indicates a routine adjustment in Morgan Stanley's beneficial ownership of Pliant Therapeutics, reducing its stake below the 5% reporting threshold. Such a change, while notable, does not inherently provide new fundamental information about Pliant Therapeutics' operational performance, financial health, or future prospects. Therefore, without additional company-specific news or financial disclosures, a 'hold' recommendation is appropriate as this filing alone does not warrant a change in investment thesis.

Keywords

Pliant Therapeutics, Morgan Stanley, Schedule 13G, Institutional Ownership, Common Stock, Shareholding, Investment, SEC Filing